Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-7
pubmed:abstractText
Acute renal failure (ARF) is often the consequence of an ischemia-reperfusion injury (IRI) and associated with high mortality. Warm ischemia (WI) is a crucial factor of tissue damage, and tissue destruction led by ischemia-reperfusion (I/R) can impact the early and long-term functional outcome. Trimetazidine (TMZ) is an anti-ischemic drug. Previously, we already verified its protective effect on a cold-ischemic pig kidney model by directly adding TMZ into the preservation solution (Faure JP, Baumert H, Han Z, Goujon JM, Favreau F, Dutheil D, Petit I, Barriere M, Tallineau C, Tillement JP, Carretier M, Mauco G, Papadopoulos V, Hauet T. Biochem Pharmacol 66: 2241-2250, 2003; Faure JP, Petit I, Zhang K, Dutheil D, Doucet C, Favreau F, Eugene M, Goujon JM, Tillement JP, Mauco G, Vandewalle A, Hauet T. Am J Transplant 4: 495-504, 2004). In this study, we aimed to study the potential effect of TMZ pretreatment (5 mg/kg iv 24 h before WI) on the injury caused by WI for 45, 60, and 90 min and reperfusion in a WI pig kidney model. Compared with sham-operated (control) and uninephrectomized animals (UNX), TMZ pretreatment significantly reduced deleterious effects after 45 min, and particularly 60 and 90 min, of WI by improving the recovery of renal function and minimizing the inflammatory response commonly prevalent in ischemic kidney injury. Compared with controls (control group and UNX group), it was observed that 1) hypoxia-inducible factor-1 (HIF-1alpha) expression occurred earlier and with a higher intensity in the TMZ-treated groups; 2) the reduction of IRI during the first week following reperfusion was correlated with an earlier and greater expression of stathmin, which is involved in the process of tubular repair; and 3) the tubulointerstitial fibrosis was reduced, particularly after 60 and 90 min of WI. In conclusion, TMZ made the warm-ischemic kidneys more resistant to the deleterious impact of a single episode of I/R and reduced early and long-term subsequent damage.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1931-857X
pubmed:author
pubmed:issnType
Print
pubmed:volume
292
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
F1082-93
pubmed:dateRevised
2011-4-28
pubmed:meshHeading
pubmed-meshheading:17341718-Animals, pubmed-meshheading:17341718-Blotting, Western, pubmed-meshheading:17341718-Creatinine, pubmed-meshheading:17341718-Gene Expression, pubmed-meshheading:17341718-Histocompatibility Antigens Class II, pubmed-meshheading:17341718-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:17341718-Kidney, pubmed-meshheading:17341718-Kidney Cortex, pubmed-meshheading:17341718-Kidney Function Tests, pubmed-meshheading:17341718-Kidney Medulla, pubmed-meshheading:17341718-Male, pubmed-meshheading:17341718-Nephrectomy, pubmed-meshheading:17341718-RNA, Messenger, pubmed-meshheading:17341718-Reperfusion Injury, pubmed-meshheading:17341718-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17341718-Stathmin, pubmed-meshheading:17341718-Survival Analysis, pubmed-meshheading:17341718-Sus scrofa, pubmed-meshheading:17341718-Time Factors, pubmed-meshheading:17341718-Treatment Outcome, pubmed-meshheading:17341718-Trimetazidine, pubmed-meshheading:17341718-Vascular Cell Adhesion Molecule-1, pubmed-meshheading:17341718-Vasodilator Agents, pubmed-meshheading:17341718-Warm Ischemia
pubmed:year
2007
pubmed:articleTitle
Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-term effects in a pig kidney model.
pubmed:affiliation
Institut National de la Santé et de la Recherche Médicale E0324, Centre Hospitalier et Universitaire de Poitiers, Poitiers, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't